FemPulse

FemPulse operates at the intersection of women’s health, medical devices, bioelectronic medicine, and digital therapeutics. Its primary differentiation is the use of a discreet, vaginally positioned ring to deliver controlled neuromodulation for overactive bladder while also supporting physiological sensing and mobile connectivity. The company’s platform is more specialized than broad digital health products because it targets urogynecology and a defined bladder-function indication. Its claimed worldwide patent coverage and combination of sensing with personalized therapy may create a platform advantage if clinical validation supports expansion beyond the initial application. FemPulse has received a CE mark for the FemPulse Ring and is pursuing an FDA-approved 12-month clinical trial, placing it in a regulatory-development phase rather than an established commercial category. Specific direct competitors are not identified in the available company information, so relative positioning against named women’s health or neuromodulation companies remains uncertain.

FemPulse’s trajectory reflects a progression from product and platform development toward clinical and regulatory validation. Founded in 2011, the company has disclosed Series B, Series C, and Series D funding rounds, but amounts are unavailable, preventing an assessment of capital efficiency or financing momentum. The FemPulse Ring is described as a removable, patient-managed neuromodulation device supported by a mobile app, while the broader bioelectronic medicine platform combines nerve stimulation, sensing, and digital connectivity. In January 2026, the company highlighted positive clinical data for presentation at the SUFU conference and added medical AI expert Wido Menhardt, PhD to its Scientific Advisory Board. The Sep 18, 2026 CE mark for overactive bladder represents the clearest recent inflection point, moving the product beyond development into a regulated-market pathway. Concurrent recruitment for a 12-month FDA-approved clinical trial indicates that U.S. expansion still depends on additional evidence and regulatory execution. With an employee count indicated at fewer than 10 people, future growth will likely depend on clinical operations, manufacturing scale-up, regulatory capacity, and commercialization partnerships, none of which are publicly detailed.